{
    "hands_on_practices": [
        {
            "introduction": "The development of cysts in Autosomal Dominant Polycystic Kidney Disease (ADPKD) is not a uniform process but rather a focal one, a phenomenon explained by the 'two-hit' hypothesis. This exercise  applies fundamental principles of probability to model the occurrence of the crucial 'second hit'—a somatic mutation that inactivates the remaining healthy gene copy in a kidney cell. By calculating the probability of this event within a single cell lineage, you will gain a quantitative understanding of how sporadic, random events at the cellular level lead to the mosaic pattern of cyst formation characteristic of the disease.",
            "id": "4801047",
            "problem": "A patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) carries a germline heterozygous variant in the polycystin-1 gene (*PKD1*). In the somatic second-hit model of cyst initiation, a focal tubular epithelial cell can initiate a cyst when a subsequent somatic event (e.g., a mutation or loss of heterozygosity (LOH)) functionally inactivates the remaining wild-type allele. Consider a single tubular epithelial cell lineage that undergoes $N=10^{6}$ mitotic divisions over time. Suppose the per-division probability of a somatic second hit that inactivates the wild-type allele is $\\mu=1\\times 10^{-7}$, and assume independence of divisions with a constant per-division risk across the lineage.\n\nUsing first principles of probability for independent Bernoulli trials, derive from the complement rule the probability $P$ that at least one effective second hit occurs somewhere in this lineage. Then evaluate $P$ numerically for the given $\\mu$ and $N$. Express your answer as a decimal fraction and round to four significant figures. Finally, explain conceptually (not as part of the numerical answer) how this focal probability relates to mosaic cyst initiation in the context of a germline heterozygous *PKD1* variant.",
            "solution": "The problem statement has been critically validated and is deemed valid. It is scientifically grounded in the accepted two-hit model of cystogenesis in Autosomal Dominant Polycystic Kidney Disease (ADPKD), well-posed with all necessary information provided, and objective in its formulation. The problem asks for the derivation and calculation of a probability based on a series of independent Bernoulli trials and a conceptual explanation of the result in a biological context.\n\nThe problem can be modeled as a sequence of $N$ independent Bernoulli trials, where each trial corresponds to a single mitotic division of a cell in the lineage. A \"success\" is defined as the occurrence of a somatic second hit that inactivates the wild-type *PKD1* allele. The probability of success in any single trial is given as $\\mu$.\n\nLet $S_i$ be the event of a second hit occurring during the $i$-th division, for $i = 1, 2, \\dots, N$.\nThe probability of this event is $P(S_i) = \\mu$.\nThe event that no second hit occurs during the $i$-th division is the complement event, denoted $S_i^c$. Its probability is $P(S_i^c) = 1 - \\mu$.\n\nThe problem asks for the probability $P$ that at least one effective second hit occurs somewhere in the lineage of $N$ divisions. This can be expressed as the probability of the union of all success events:\n$$P = P(S_1 \\cup S_2 \\cup \\dots \\cup S_N)$$\nCalculating this directly is cumbersome. It is more straightforward to use the complement rule, as requested by the problem. The complement of \"at least one hit\" is \"zero hits\".\nLet $A$ be the event that at least one hit occurs in $N$ divisions. The complement event, $A^c$, is that no hits occur in any of the $N$ divisions.\n$$P(A) = 1 - P(A^c)$$\nThe event $A^c$ corresponds to the intersection of the events where no hit occurred in each individual division:\n$$A^c = S_1^c \\cap S_2^c \\cap \\dots \\cap S_N^c$$\nSince the divisions are assumed to be independent events, the probability of the intersection is the product of the individual probabilities:\n$$P(A^c) = P(S_1^c) \\times P(S_2^c) \\times \\dots \\times P(S_N^c) = \\prod_{i=1}^{N} P(S_i^c)$$\nSince $P(S_i^c) = 1 - \\mu$ for all $i$, this simplifies to:\n$$P(A^c) = (1 - \\mu)^N$$\nSubstituting this back into the complement rule, we obtain the desired expression for $P$:\n$$P = 1 - (1 - \\mu)^N$$\nThis is the derived probability that at least one effective second hit occurs in the lineage.\n\nNow, we evaluate $P$ numerically using the given values:\nNumber of divisions, $N = 10^6$.\nPer-division probability of a second hit, $\\mu = 1 \\times 10^{-7}$.\n\nSubstituting these values into the derived formula:\n$$P = 1 - (1 - 1 \\times 10^{-7})^{10^6}$$\n$$P = 1 - (1 - 0.0000001)^{1000000}$$\n$$P = 1 - (0.9999999)^{1000000}$$\nCalculating the value of the term $(0.9999999)^{1000000}$:\n$$(0.9999999)^{1000000} \\approx 0.90483736$$\nTherefore, the probability $P$ is:\n$$P \\approx 1 - 0.90483736 = 0.09516264$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $9$, $5$, $1$, and $6$. The fifth significant figure is $2$, which is less than $5$, so we do not round up.\n$$P \\approx 0.09516$$\n\nConceptually, this probability $P \\approx 0.09516$ (or about $9.5\\%$) represents the risk that a *single* tubular epithelial cell lineage, starting from a cell with a germline *PKD1* mutation, will give rise to a cyst-initiating cell over the course of $10^6$ divisions. This risk for a single lineage is relatively low.\n\nHowever, the human kidney is composed of millions of renal tubules, each containing thousands of such epithelial cells. Each of these cells can be considered the progenitor of a distinct lineage, running an independent \"probabilistic experiment\". If there are, for example, $M$ such independent lineages in the kidneys, the probability that *at least one* of them initiates a cyst is $1 - (1-P)^M$. Given that $M$ is a very large number, this probability approaches $1$ (certainty), even though $P$ itself is small. This explains the high penetrance of the disease—why individuals with a germline *PKD1* mutation almost invariably develop numerous cysts. The cysts arise from focal, sporadic second-hit events, meaning the kidney tissue becomes a \"mosaic\" of a vast majority of cells that are heterozygous at the *PKD1* locus (one hit) and a small number of clonal cell populations that are functionally null for *PKD1* (two hits) and which go on to form the cysts. This calculated focal probability is the fundamental unit of risk that, when scaled up to the level of the entire organ, accounts for the clinical phenotype of ADPKD.",
            "answer": "$$\\boxed{0.09516}$$"
        },
        {
            "introduction": "Once cysts form, their progressive expansion leads to a measurable increase in Total Kidney Volume (TKV), a critical surrogate biomarker for tracking disease progression in ADPKD. This practice  challenges you to apply a continuous exponential growth model to quantify the rate of kidney enlargement from serial imaging data. By deriving the growth parameter and calculating the height-adjusted TKV (htTKV), you will develop the quantitative skills needed to interpret disease trajectory and stratify patient risk based on validated biomarkers.",
            "id": "4800872",
            "problem": "A $42$-year-old adult with Autosomal Dominant Polycystic Kidney Disease (ADPKD) is followed longitudinally with serial imaging of Total Kidney Volume (TKV). TKV is considered a validated surrogate biomarker of disease progression in ADPKD when measured reproducibly and adjusted for body size. Height-adjusted Total Kidney Volume (htTKV) is defined as the ratio of total kidney volume to patient height. Assume the trajectory of TKV over time $t$ (in years) follows continuous exponential growth such that the instantaneous rate of change of volume is proportional to the current volume, consistent with cyst burden expansion under relatively stable physiological conditions. The measured TKV increases from $900$ mL at baseline ($t=0$) to $1080$ mL at $t=2$ years, and the patient’s height is $1.70$ m.\n\nStarting from the definition that the instantaneous growth rate is proportional to the current volume, derive the continuous growth parameter $r$ (in per year) that characterizes this trajectory between the two time points. Then compute the height-adjusted total kidney volume at baseline and at $t=2$ years. Express $r$ as a decimal per year and each htTKV in $\\text{mL/m}$.\n\nRound all reported quantities to four significant figures. Provide the final answer in the order: $r$, baseline htTKV, $2$-year htTKV.",
            "solution": "The problem statement is deemed valid. It is scientifically grounded, well-posed, and objective. The provided clinical context, model, and data are consistent and sufficient for deriving a unique solution.\n\nThe problem states that the instantaneous rate of change of Total Kidney Volume (TKV), denoted by $V(t)$, is proportional to the current volume. This is the definition of continuous exponential growth, which can be expressed as the following first-order linear ordinary differential equation:\n$$\n\\frac{dV}{dt} = rV\n$$\nwhere $r$ is the continuous growth parameter in units of per year.\n\nThis differential equation can be solved by separation of variables:\n$$\n\\frac{dV}{V} = r \\, dt\n$$\nIntegrating both sides gives:\n$$\n\\int \\frac{1}{V} \\, dV = \\int r \\, dt\n$$\n$$\n\\ln|V| = rt + C\n$$\nwhere $C$ is the constant of integration. We can solve for $V$ by exponentiating both sides:\n$$\n|V| = \\exp(rt + C) = \\exp(C) \\exp(rt)\n$$\nSince volume $V$ must be positive, we can drop the absolute value. We define a new constant $V_0 = \\exp(C)$, which represents the initial volume at time $t=0$. The solution to the differential equation is the standard exponential growth model:\n$$\nV(t) = V_0 \\exp(rt)\n$$\n\nThe problem provides the following data:\n-   The baseline TKV at $t=0$ is $V(0) = 900 \\text{ mL}$. This directly gives us the value of $V_0$. So, $V_0 = 900 \\text{ mL}$.\n-   The TKV at $t=2$ years is $V(2) = 1080 \\text{ mL}$.\n\nWe can now write the specific model for this patient's TKV growth:\n$$\nV(t) = 900 \\exp(rt)\n$$\nTo find the growth parameter $r$, we substitute the second data point, $V(2) = 1080 \\text{ mL}$, into the equation:\n$$\n1080 = 900 \\exp(r \\cdot 2)\n$$\nFirst, we isolate the exponential term by dividing both sides by $900$:\n$$\n\\frac{1080}{900} = \\exp(2r)\n$$\n$$\n1.2 = \\exp(2r)\n$$\nNext, we take the natural logarithm of both sides to solve for the exponent:\n$$\n\\ln(1.2) = 2r\n$$\nFinally, we solve for $r$:\n$$\nr = \\frac{\\ln(1.2)}{2}\n$$\nNow, we compute the numerical value and round to four significant figures.\n$$\nr \\approx \\frac{0.18232155679}{2} \\approx 0.09116077839 \\text{ year}^{-1}\n$$\nRounding to four significant figures, we get:\n$$\nr \\approx 0.09116 \\text{ year}^{-1}\n$$\n\nNext, we are asked to compute the height-adjusted total kidney volume (htTKV) at baseline ($t=0$) and at $t=2$ years. The patient's height is given as $h = 1.70 \\text{ m}$. The definition of htTKV is:\n$$\n\\text{htTKV} = \\frac{\\text{TKV}}{h}\n$$\n\nThe baseline htTKV is calculated using $V(0) = 900 \\text{ mL}$:\n$$\n\\text{htTKV}(0) = \\frac{V(0)}{h} = \\frac{900 \\text{ mL}}{1.70 \\text{ m}} \\approx 529.41176 \\text{ mL/m}\n$$\nRounding to four significant figures, we get:\n$$\n\\text{htTKV}(0) \\approx 529.4 \\text{ mL/m}\n$$\n\nThe htTKV at $t=2$ years is calculated using $V(2) = 1080 \\text{ mL}$:\n$$\n\\text{htTKV}(2) = \\frac{V(2)}{h} = \\frac{1080 \\text{ mL}}{1.70 \\text{ m}} \\approx 635.29411 \\text{ mL/m}\n$$\nRounding to four significant figures, we get:\n$$\n\\text{htTKV}(2) \\approx 635.3 \\text{ mL/m}\n$$\n\nThe three requested quantities, rounded to four significant figures, are:\n1.  Growth parameter $r$: $0.09116$\n2.  Baseline htTKV: $529.4$\n3.  $2$-year htTKV: $635.3$",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.09116 & 529.4 & 635.3\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "A cornerstone of modern ADPKD management involves suppressing the hormone vasopressin, a key driver of cyst growth, by maintaining high fluid intake and dilute urine. This hands-on exercise  puts you in the clinician's role of translating this physiological goal into a practical patient recommendation. Using the principles of water balance and osmoregulation, you will calculate the minimal daily water intake required to achieve a target urine osmolality, reinforcing the quantitative basis behind this important therapeutic intervention.",
            "id": "4800942",
            "problem": "A patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) is counseled to suppress Arginine Vasopressin (AVP) signaling by maintaining dilute urine. In a steady-state over a day, assume that daily osmole excretion equals daily osmole intake (osmole load) and that water balance is governed by conservation of mass. The daily osmole load is $600$ mOsm. The clinical target is urine osmolality less than or equal to $280$ mOsm/kg. Environmental conditions are temperate, and insensible water losses (via skin and respiratory tract) are $0.80$ L/day. Assume urine density is approximately equal to that of pure water so that $1$ kg of urine is $1$ L. Under these assumptions, derive from first principles the minimal daily oral water intake required to ensure that daily urine osmolality is at most $280$ mOsm/kg in steady-state. Round your final numeric answer to three significant figures and express it in L/day.",
            "solution": "The problem statement has been validated and is scientifically sound, presenting a standard clinical calculation based on principles of osmoregulation and water balance. All necessary parameters are provided.\n\nThe goal is to find the minimal daily oral water intake required to keep urine osmolality at or below a target value.\n\n**1. Define the relationship between osmole excretion, urine volume, and urine osmolality.**\nIn a steady state, the total amount of solutes excreted in the urine per day ($E_{osm}$) must equal the daily osmole load ($L_{osm}$).\n$$E_{osm} = L_{osm} = 600 \\text{ mOsm/day}$$\nUrine osmolality ($U_{osm}$) is defined as the concentration of solutes in the urine:\n$$U_{osm} = \\frac{E_{osm}}{V_{urine}}$$\nwhere $V_{urine}$ is the daily urine volume.\n\n**2. Determine the minimum required urine volume.**\nThe clinical target is $U_{osm} \\le 280$ mOsm/kg. To find the minimal required water intake, we must first find the minimal required urine output that satisfies this condition. From the equation above, we can express urine volume as:\n$$V_{urine} = \\frac{E_{osm}}{U_{osm}}$$\nTo satisfy the inequality $U_{osm} \\le 280$ mOsm/kg, the urine volume must be:\n$$V_{urine} \\ge \\frac{600 \\text{ mOsm/day}}{280 \\text{ mOsm/kg}}$$\nThe minimum required urine volume ($V_{urine,min}$) occurs when the urine osmolality is at its maximum allowed value, $U_{osm,max} = 280$ mOsm/kg.\nAssuming the density of urine is approximately $1$ kg/L:\n$$V_{urine,min} = \\frac{600 \\text{ mOsm/day}}{280 \\text{ mOsm/L}} = \\frac{60}{28} \\text{ L/day} = \\frac{15}{7} \\text{ L/day}$$\n$$V_{urine,min} \\approx 2.142857 \\text{ L/day}$$\n\n**3. Apply the principle of water balance.**\nIn steady state, total daily water intake must equal total daily water output.\n$$V_{intake} = V_{output} = V_{urine} + V_{insensible}$$\nThe minimal required oral intake ($V_{intake,min}$) corresponds to the minimal required urine volume ($V_{urine,min}$).\n$$V_{intake,min} = V_{urine,min} + V_{insensible}$$\n\n**4. Calculate the final value.**\nSubstituting the known values:\n$$V_{intake,min} = \\left(\\frac{15}{7}\\right) \\text{ L/day} + 0.80 \\text{ L/day}$$\n$$V_{intake,min} \\approx 2.142857 \\text{ L/day} + 0.80 \\text{ L/day} = 2.942857 \\text{ L/day}$$\nRounding the final answer to three significant figures, we get:\n$$V_{intake,min} \\approx 2.94 \\text{ L/day}$$",
            "answer": "$$\n\\boxed{2.94}\n$$"
        }
    ]
}